ZYMEWORKS INC. Accounts Receivable
ZYMEWORKS INC. (ZYME) had Accounts Receivable of $5.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $5.93M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $4.67M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $4.64M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $29.35M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $5.93M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.67M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $4.64M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $29.35M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.63M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $24.59M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $55.81M 10-K · filed 2026-03-02 |
| 2024-09-30 | $23.70M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $32.08M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $30.95M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $19.48M 10-K · filed 2025-03-05 |
| 2023-09-30 | $67.27M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $48.82M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $66.92M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $33.40M 10-K · filed 2024-03-06 |
| 2022-09-30 | $6.73M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $15.61M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |